ArticleHuman vaccines & immunotherapeutics2022
Burden of severe bronchiolitis in children up to 2 years of age in Spain from 2012 to 2017.
Article in Human vaccines & immunotherapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06139029 (Comparison of 3% Normal Saline Nebulization Versus Steroid Nebulization in the Treatment of Bronchiolitis), which is not on this map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparison of 3% Normal Saline Nebulization Versus Steroid Nebulization in the Treatment of Bronchiolitis
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Prevalence of common respiratory viruses of infants with respiratory tract infections in European countries in the past decade: a systematic review and meta-analysis comparing between the pre-COVID-19, pandemic, and post-COVID-19 periods.European journal of pediatrics · 2026Pooled it
- Incidence of Respiratory Syncytial Virus Infection Among Patients Aged Less Than 2 Years: A Retrospective Study From an Italian Southern Region in Years 2018-2023.Influenza and other respiratory viruses · 2026Observational
- Antibiotic Therapy and Factors Predicting Prolonged Hospitalization Among Children Under Three Years Diagnosed With Respiratory Syncytial Virus-Associated Lower Respiratory Infection.Immunity, inflammation and disease · 2026Article
- Real-World Evidence Evaluation of Respiratory Syncytial Virus (RSV) Vaccines: Deep Dive into Vaccine Adverse Events Reporting System.Diseases (Basel, Switzerland) · 2026Article
- Observational
- Assessing the Impact of Nirsevimab Immunization on RSV Bronchiolitis Hospital Admissions and Their Severity: A Case-Control Study and Comparison With Pre- and Post-COVID-19 Seasons in a Tertiary Pediatric Hospital.Pediatric pulmonology · 2025Article
- Cost-Effectiveness Analysis of Nirsevimab for the Prevention of Respiratory Syncytial Virus among Italian Infants.Clinical drug investigation · 2025Article
- Estimating the economically justifiable price of nirsevimab versus standard of practice for the prevention of respiratory syncytial virus infections in neonates and infants in Spain: a cost-utility modelling study.BMJ public health · 2025Article
- Modelling the potential clinical and economic impact of universal immunisation with nirsevimab versus standard of practice for protecting all neonates and infants in their first respiratory syncytial virus season in Spain.BMC infectious diseases · 2024Article
- Impact of universal immunization program with monoclonal antibody nirsevimab on reducing the burden of serious bronchiolitis that need pediatric intensive care.European journal of pediatrics · 2024Observational
- Impact of twelve immunization-preventable infectious diseases on population health using disability-adjusted life years (DALYs) in Spain.BMC infectious diseases · 2024Article
- Respiratory Syncytial Virus (RSV) Burden in Infants in the Kingdom of Saudi Arabia and the Impact of All-Infant RSV Protection: A Modeling Study.Advances in therapy · 2024Article
- Clinical and economic burden of respiratory syncytial virus in children aged 0-5 years in Italy.Italian journal of pediatrics · 2024Observational
- Estimated Respiratory Syncytial Virus-Related Hospitalizations and Deaths Among Children and Adults in Spain, 2016-2019.Infectious diseases and therapy · 2024Article
- Predictors of prolonged length of hospital stay and in-hospital mortality in patients aged 1-24 months with acute bronchiolitis in Douala, Cameroon.BMC pediatrics · 2024Article
- Evaluation of antibody-based preventive alternatives for respiratory syncytial virus: a novel multi-criteria decision analysis framework and assessment of nirsevimab in Spain.BMC infectious diseases · 2024Article
- Bronchiolitis, Regardless of Its Etiology and Severity, Is Associated With Increased Risk of Asthma: A Population-Based Study.The Journal of infectious diseases · 2023Article
- Human Respiratory Syncytial Virus Epidemiological Burden in Pediatric Outpatients in Italy: A Systematic Review.Vaccines · 2023Review
- Risk Factors for Severe Respiratory Syncytial Virus Infection in Hospitalized Children.Viruses · 2023Article
- Respiratory syncytial virus-associated hospitalization in children aged <2 years in Spain from 2018 to 2021.Human vaccines & immunotherapeutics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bronchiolitis represents a heavy burden of disease in children under 2 years of age in our society due to the high infectivity of the Respiratory Syncytial Virus [RSV] and the vulnerability of the youngest children.The objective of this retrospective epidemiological study was to show the burden of severe bronchiolitis in Spain through population-based estimates of hospitalizations due to bronchiolitis in children up to 24 months old during a 6-year period (2012-2017).A total of 100,115 cases of bronchiolitis required hospitalization in Spain from 2012 to 2017. Most cases of bronchiolitis that required hospitalization were in infants under 3 months of age. The hospitalization rate for bronchiolitis for children under 1 year of age was 3,838.27 per 100,000 healthy children. During the 6-year study period, a total of 82 deaths due to bronchiolitis were reported among hospitalized infants. Among these deaths, more than 50% were in patients younger than 3 months of age. The annual average cost to the National Health Care System was €58 M, with a mean hospitalization cost of €3,512 per case.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.